Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Werner Poewe

Showing results (471-480 of 602) with videos related to

Pageof 61
Sort By:
Clinical Neuropharmacology|January 18, 2014
Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized studyMurat Emre, Werner Poewe, Peter Paul De Deyn, et al.
Neurology|March 13, 2020
Seeing ophthalmologic problems in Parkinson disease: Results of a visual impairment questionnaireCarlijn D J M Borm, Femke Visser, Mario Werkmann, et al.
Neurology|March 13, 2020
Left-hemispheric predominance of nigrostriatal deficit in isolated REM sleep behavior disorderAlex Iranzo, Ambra Stefani, Aida Niñerola-Baizan, et al.
Journal of Neurology|August 20, 2024
Opicapone for the treatment of early wearing-off in levodopa-treated Parkinson's disease: pooled analysis of patient level data from two randomized open-label studiesJoaquim J Ferreira, Jee-Young Lee, Hyeo-Il Ma, et al.
BMC Neurology|June 27, 2019
Towards seeing the visual impairments in Parkinson's disease: protocol for a multicentre observational, cross-sectional studyCarlijn D J M Borm, Mario Werkmann, Femke Visser, et al.
Journal of Neurology|August 1, 2025
Correction: Opicapone for the treatment of early wearing-off in levodopa-treated Parkinson's disease: pooled analysis of patient level data from two randomized open-label studiesJoaquim J Ferreira, Jee-Young Lee, Hyeo-Il Ma, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 7, 2011
The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotensionAnne Pavy-Le Traon, Gerard Amarenco, Susanne Duerr, et al.
Movement Disorders Clinical Practice|April 25, 2024
Early Screening for the Parkinson Variant of Multiple System Atrophy: A 6-Item ScoreAlessandra Fanciulli, Iva Stankovic, Omer Avraham, et al.
The Lancet. Neurology|June 21, 2020
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trialDieter Volc, Werner Poewe, Alexandra Kutzelnigg, et al.
American Journal of Human Genetics|November 15, 2016
Haploinsufficiency of KMT2B, Encoding the Lysine-Specific Histone Methyltransferase 2B, Results in Early-Onset Generalized DystoniaMichael Zech, Sylvia Boesch, Esther M Maier, et al.
Pageof 61

Showing results (471-480 of 602) with videos related to

Sort By:
Pageof 61
Clinical Neuropharmacology|January 18, 2014
Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized studyMurat Emre, Werner Poewe, Peter Paul De Deyn, et al.
Neurology|March 13, 2020
Seeing ophthalmologic problems in Parkinson disease: Results of a visual impairment questionnaireCarlijn D J M Borm, Femke Visser, Mario Werkmann, et al.
Neurology|March 13, 2020
Left-hemispheric predominance of nigrostriatal deficit in isolated REM sleep behavior disorderAlex Iranzo, Ambra Stefani, Aida Niñerola-Baizan, et al.
Journal of Neurology|August 20, 2024
Opicapone for the treatment of early wearing-off in levodopa-treated Parkinson's disease: pooled analysis of patient level data from two randomized open-label studiesJoaquim J Ferreira, Jee-Young Lee, Hyeo-Il Ma, et al.
BMC Neurology|June 27, 2019
Towards seeing the visual impairments in Parkinson's disease: protocol for a multicentre observational, cross-sectional studyCarlijn D J M Borm, Mario Werkmann, Femke Visser, et al.
Journal of Neurology|August 1, 2025
Correction: Opicapone for the treatment of early wearing-off in levodopa-treated Parkinson's disease: pooled analysis of patient level data from two randomized open-label studiesJoaquim J Ferreira, Jee-Young Lee, Hyeo-Il Ma, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 7, 2011
The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotensionAnne Pavy-Le Traon, Gerard Amarenco, Susanne Duerr, et al.
Movement Disorders Clinical Practice|April 25, 2024
Early Screening for the Parkinson Variant of Multiple System Atrophy: A 6-Item ScoreAlessandra Fanciulli, Iva Stankovic, Omer Avraham, et al.
The Lancet. Neurology|June 21, 2020
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trialDieter Volc, Werner Poewe, Alexandra Kutzelnigg, et al.
American Journal of Human Genetics|November 15, 2016
Haploinsufficiency of KMT2B, Encoding the Lysine-Specific Histone Methyltransferase 2B, Results in Early-Onset Generalized DystoniaMichael Zech, Sylvia Boesch, Esther M Maier, et al.
Pageof 61